Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

BeyondSpring Inc.

NASDAQ: BYSI · Life Sciences · 7 alerts · CIK 1677940

Share price
$0.5788Close, Nov 16
Market cap
$24M
Shares outstanding
41.41MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All BeyondSpring Inc. filings on SEC EDGAR ↗

4:30 PM ET 8-K
Divestiture

BeyondSpring Divestiture to Biolin Investment Limited

BeyondSpring Inc. completed the sale of its entire issued share capital in BeyondSpring Ltd. to Biolin Investment Limited, effectively divesting its interests in Dalian Wanchunbulin Pharmaceuticals and SEED Therapeutics. The transaction was for non-cash consideration, consisting of a strategic collaboration where the investor funds and completes the China portion of the DUBLIN-4 Phase 3 clinical trial. BeyondSpring retains rights to the clinical data generated from the trial and a potential equity clawback if enrollment targets are not met.

Counterparty
Biolin Investment Limited
Term
3 years
4:31 PM ET 8-K
Nasdaq/NYSE Compliance Notice

BeyondSpring Nasdaq/NYSE Compliance Notice

BeyondSpring Inc. received a deficiency notice from Nasdaq on September 29, 2026, because its market value of listed securities (MVLS) fell below the $35 million minimum requirement for 30 consecutive business days. The company has 180 calendar days, or until March 29, 2027, to regain compliance by maintaining a MVLS of at least $35 million for ten consecutive business days. The notice does not result in immediate delisting, and the company's ordinary shares continue to trade on the Nasdaq Capital Market.

Counterparty
The Nasdaq Stock Market LLC
Term
180 days
7:04 AM ET 8-K
Divestiture

BeyondSpring Divestiture to Biolin Investment Limited

BeyondSpring entered into a definitive agreement to sell its majority equity interest in its Chinese subsidiary, Bulin, to Biolin Investment Limited. In exchange for the equity, the investor will fund and conduct the China portion of the global Phase 3 DUBLIN-4 trial for Plinabulin, which is expected to cover approximately 50% of the total trial enrollment.

Counterparty
Biolin Investment Limited
Term
3 years
Earnings call
Sep 29, 2026, 8:00 AM ET
4:31 PM ET 8-K
Nasdaq/NYSE Compliance Notice

BeyondSpring Nasdaq/NYSE Compliance Notice

BeyondSpring Inc. received a deficiency notice from Nasdaq on September 17, 2026, because its ordinary shares closed below the $1.00 minimum bid price for 30 consecutive business days. The company has 180 calendar days, or until March 16, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days.

Counterparty
The Nasdaq Stock Market LLC
Term
180 days

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.